COMPANY PROFILE

Predicta Biosciences

Explore full profile

Revolutionize Precision Oncology with Predicta Biosciences

Cambridge, United StatesFounded 2023Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Predicta Biosciences

Predicta Biosciences is a precision oncology company that leverages cutting-edge multiomics and artificial intelligence (AI) to develop innovative diagnostic and therapeutic products. The company operates in the healthcare sector, specifically focusing on oncology, and serves healthcare providers and payers. Predicta Biosciences' core business model revolves around creating diagnostic solutions that ensure patients receive optimal therapy throughout their treatment journey. By utilizing small blood-based samples, the company provides clear and actionable data to determine whether patients will respond to specific treatments, thereby eliminating the need for invasive bone marrow biopsies. Predicta Biosciences generates revenue through the sale of its diagnostic tests and data-driven insights to healthcare providers and payers. The company's platform also fuels a vast database, which is mined using AI tools to discover novel therapeutic targets, further enhancing its product offerings. Predicta Biosciences empowers clinicians with the necessary tools and knowledge to make informed decisions, ultimately aiming to improve patient outcomes.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2023
Headquarters: Cambridge, United States
Employees: 11
Open positions: 1
Dealroom signal: 52.7/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Oct 2025	$23M	$94M	Lightchain-capital · BrightEdge · Illumina Ventures · Binney Street Capital	↗
SEED✓Equity / VC	Jul 2024	$5.2M	$21M	Illumina Ventures · Engine Ventures · American Cancer Society · Time Partners	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Predicta Biosciences website traffic

Latest recorded traffic for Predicta Biosciences is 2K monthly website visits, down 9.1% over the last three months. Predicta Biosciences's team grew 0% over the past year.

Latest monthly visits2K 3-month web change-9.1% 1-year team growth0%

Monthly website visitsSep 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

R&D ScientistCambridge, Massachusetts, United States, Northern America, Americas · Data Science & Engineering · Aug 22, 2026 Senior ScientistCambridge, MA · Data Science & Engineering · Jul 10, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SESentanteDeveloping a radiation-reducing manipulator and a minimally invasive coronary robotic system for endovascular procedures	Kaunas, Lithuania	Operational	39	$9.1M	$26M
A4A4CellDevelops New technology named SPAchip (Suspended Planar-Array Chips) offering a perfect way to track living single cell	Madrid, Spain	Operational
HSHirotsu Bio ScienceDeveloped N-Nose, a non-invasive cancer screening product using nematode worms to detect early-stage cancers through urine samples	Tokyo, Japan	Operational
NANanoligentThe research and development to clinical phases of innovative cancer treatments based on protein nanoparticles	Cerdanyola del Vallès, Spain	Operational
CACarvolixThe new generation of minimally invasive implants to treat diseases of the heart, aorta, and urinary incontinence	Paris, France	Operational
UDUniversal Medical Imaging DiagnosticOffers a holistic alternative and complementary approach to overall health that uses non-invasive, non-radioactive and painless imaging of the whole body	Los Angeles, United States	Operational
4M4D MedicalImproving global health by providing unique and non-invasive imaging technologies that enable unprecedented insight into pulmonary functioning, critical in the analysis and management of respiratory diseases	Melbourne, Australia	Operational
CECelluminovaSpecializes in the development of new tools for stem cell research, including cancer stem cells	Norrköpings kommun, Sweden	Operational